000060875 001__ 60875
000060875 005__ 20170503142843.0
000060875 0247_ $$2doi$$a10.1128/JCM.01230-13
000060875 0248_ $$2sideral$$a82557
000060875 037__ $$aART-2013-82557
000060875 041__ $$aeng
000060875 100__ $$aCantón, E.
000060875 245__ $$aEpidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method
000060875 260__ $$c2013
000060875 5060_ $$aAccess copy available to the general public$$fUnrestricted
000060875 5203_ $$aIn the absence of clinical breakpoints (CBP), epidemiological cutoff values (ECVs) are useful to separate wild-type (WT) isolates (without mechanisms of resistance) from non-WT isolates (those that can harbor some resistance mechanisms), which is the goal of susceptibility tests. Sensititre YeastOne (SYO) is a widely used method to determine susceptibility of Candida spp. to antifungal agents. The CLSI CBP have been established, but not for the SYO method. The ECVs for four azoles, obtained using MIC distributions determined by the SYO method, were calculated via five methods (three statistical methods and based on the MIC50 and modal MIC). Respectively, the median ECVs (in mg/liter) of the five methods for fluconazole, itraconazole, posaconazole, and voriconazole (in parentheses: the percentage of isolates inhibited by MICs equal to or less than the ECVs; the number of isolates tested) were as follows: 2 (94.4%; 944), 0.5 (96.7%; 942), 0.25 (97.6%; 673), and 0.06 (96.7%; 849) for Candida albicans; 4 (86.1%; 642), 0.5 (99.4%; 642), 0.12 (93.9%; 392), and 0.06 (86.9%; 559) for C. parapsilosis; 8 (94.9%; 175), 1 (93.7%; 175), 2 (93.6%; 125), and 0.25 (90.4%; 167) for C. tropicalis; 128 (98.6%; 212), 4 (95.8%; 212), 4 (96.0%; 173), and 2 (98.5; 205) for C. glabrata; 256 (100%; 53), 1 (98.1%; 53), 1 (100%; 33), and 1 (97.9%; 48) for C. krusei; 4 (89.2%; 93), 0.5 (100%; 93), 0.25 (100%; 33), and 0.06 (87.7%; 73) for C. orthopsilosis. All methods included =94% of isolates and yielded similar ECVs (within 1 dilution). These ECVs would be suitable for monitoring emergence of isolates with reduced susceptibility by using the SYO method.
000060875 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000060875 590__ $$a4.232$$b2013
000060875 591__ $$aMICROBIOLOGY$$b23 / 118 = 0.195$$c2013$$dQ1$$eT1
000060875 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000060875 700__ $$aPemán, J.
000060875 700__ $$aIñiguez, C.
000060875 700__ $$aHervás, D.
000060875 700__ $$aLopez-Hontangas, J.
000060875 700__ $$aPina-Vaz, C.
000060875 700__ $$aCamarena, J.J.
000060875 700__ $$aCampos-Herrero, I.
000060875 700__ $$aGarcía-García, I.
000060875 700__ $$aGarcía-Tapia, A.M.
000060875 700__ $$aGuna, R.
000060875 700__ $$aMerino, P.
000060875 700__ $$aDel Molino, L.P.
000060875 700__ $$0(orcid)0000-0002-7068-0983$$aRubio, C.$$uUniversidad de Zaragoza
000060875 700__ $$aSuárez, A.
000060875 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDepartamento de Microbiología, Medicina Preventiva y Salud Pública$$cMicrobiología
000060875 773__ $$g51, 8 (2013), 2691-2695$$pJ. clin. microbiol.$$tJOURNAL OF CLINICAL MICROBIOLOGY$$x0095-1137
000060875 8564_ $$s137807$$uhttp://zaguan.unizar.es/record/60875/files/texto_completo.pdf$$yVersión publicada
000060875 8564_ $$s134953$$uhttp://zaguan.unizar.es/record/60875/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000060875 909CO $$ooai:zaguan.unizar.es:60875$$particulos$$pdriver
000060875 951__ $$a2017-05-03-14:22:50
000060875 980__ $$aARTICLE